Get started
Author

Jianhua Shi

Observed name: SHI Jianhua
ORCID: 0000-0001-7009-8945
Observed ORCID: 0000-0001-7009-8945
OpenAlex ID: A5021425509
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial
2024 · Ying Cheng, Jianhua Chen, et al. · Nature Medicine · 165
PDF
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
2024 · Ziming Li, Xiaomin Dang, et al. · The Lancet Respiratory Medicine · 57
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
2025 · James Chih-Hsin Yang, Mengzhao Wang, et al. · Journal of Clinical Oncology · 35
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial
2024 · Baohui Han, Trevor Feinstein, et al. · The Lancet Respiratory Medicine · 26
Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1/2 trial
2025 · Zhichao Tan, Yan Wu, et al. · Journal for ImmunoTherapy of Cancer · 18
PDF
HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer
2023 · Tao Jiang, Qiqi Jin, et al. · Clinical Cancer Research · 18
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study
2024 · Jin-Ji Yang, Jianying Zhou, et al. · The Lancet Respiratory Medicine · 10
Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study
2025 · Shun Lu, Oleksandr Vynnychenko, et al. · The Lancet Respiratory Medicine · 7
Phase 3 study of benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC).
2025 · Yuankai Shi, Longhua Sun, et al. · Journal of Clinical Oncology · 7
PDF
The Association of Dietary Diversity with Hyperuricemia among Community Inhabitants in Shanghai, China: A Prospective Research
2024 · Xiaoli Xu, Mengru He, et al. · Nutrients · 7
PDF
Association between EAT-Lancet diet adherence and incident type 2 diabetes in Shanghai adults: a prospective cohort study
2025 · Xiaoli Xu, Genming Zhao, et al. · BMC Public Health · 2
PDF
Secular trends in age at menarche among Han Chinese females in Shanghai: a large-scale community-based study
2025 · Xiaoli Xu, Genming Zhao, et al. · BMC Women s Health · 2
PDF
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial
2025 · Dan-Yun Ruan, Wen-Wen Huang, et al. · Signal Transduction and Targeted Therapy · 2
A phase 1 study of the OX40 agonist BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced NSCLC, HNSCC, or NPC.
2025 · Min Hee Hong, Byoung Chul Cho, et al. · Journal of Clinical Oncology · 1
PDF
Preliminary results of ZG005, a bispecific antibody targeting PD-1 and TIGIT, as monotherapy in patients with advanced cervical cancer.
2025 · Hanmei Lou, Shuxia Cheng, et al. · Journal of Clinical Oncology · 1
Preliminary results from a phase I expansion study of ZG005, a bispecific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors.
2024 · Shukui Qin, Ying Cheng, et al. · Journal of Clinical Oncology · 1
PDF
Transcriptomic Identification of Renin—Angiotensin System-Related Candidate Biomarkers and External Testing of a Hypertension Diagnostic Model
2026 · Jing Bai, Yan Wang, et al. · Journal of Visualized Experiments
Association of Legume Intake with Incident Hyperuricemia: A Prospective Cohort Study in Shanghai Adult Residents
2026 · Xiaoli Xu, Mengru He, et al. · Nutrients
PDF
Correction: Association between EAT-Lancet diet adherence and incident type 2 diabetes in Shanghai adults: a prospective cohort study
2026 · Xiaoli Xu, Genming Zhao, et al. · BMC Public Health
PDF
Risk factors and predictive nomograms for early mortality in patients with thyroid cancer lung metastasis based on the SEER database and a Chinese population study
2025 · Rui Lv, Yuting Yuan, et al. · Gland Surgery
Final analysis of a multicenter, open-label, phase 2 study evaluating the efficacy and safety of tislelizumab (TIS) in combination with fruquintinib (F) in patients (pts) with selected solid tumors.
2025 · Keun-Wook Lee, Yanqiao Zhang, et al. · Journal of Clinical Oncology
PDF
Decreased prevalence of alcohol use and related sociodemographic factors in an urban district of Shanghai, China: Evidence from three cross-sectional surveys (2010–2021)
2024 · Li Cao, Xiaolin Qian, et al. · Drug and Alcohol Dependence
Supplementary Data 1 from HLA-I evolutionary divergence confers response to PD-1 blockade plus chemotherapy in untreated advanced non-small-cell lung cancer
2024 · Tao Jiang, Qiqi Jin, et al.
Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer
2023 · Tao Jiang, Qiqi Jin, et al.
PDF
Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer
2023 · Tao Jiang, Qiqi Jin, et al.
Works count: 32
Citation count: 359
H-index: 7
I10-index: 7
Year
Topic
Type